SCHEMBL5493591

SCHEMBL5493591

O=C(O)C1CSC(c2ccc(Cl)cc2)=N1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 1/20 0.46
GPR35 Q9HC97 1/20 0.45
HTR2B P41595 1/20 0.39
TSHR P16473 2/20 0.38
KDM4E B2RXH2 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
ALAD P13716 1/20 0.35
POLB P06746 1/20 0.35
SRD5A2 P31213 1/20 0.34
ALOX5 P09917 1/20 0.34
KMO O15229 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9231796 0.85 GPR35 (0.56) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL12872412 0.85 GPR35 (0.56) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL723266 0.85 HTR2B (0.49) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL4415767 0.85 HTR2B (0.49) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL1683655 0.85 HTR2B (0.49) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL5494654 0.84 GPR35 (0.45) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL28391370 0.84 GPR35 (0.45) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL28391371 0.84 GPR35 (0.45) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL10425856 0.82 MAPT (0.52) MAPTALOX15MAPK1GPR35HTR2B
SCHEMBL5500838 0.82 GPR35 (0.44) MAPTALOX15MAPK1GPR35HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1835937-B Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV 2012-07-18 CN claimed
CN-1835937-B Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV 2012-07-18 CN disclosed
EP-1656360-B1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2007-08-15 EP disclosed
CN-1835937-A Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2006-09-20 CN disclosed
EP-1656360-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-17 EP disclosed
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) JASSEN PHARMACEUTICA N.V. (BE) 2005-01-20 US disclosed
WO-2004113309-A1 THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014952-A1 Novel thiazoline derivatives as selective androgen receptor modulators (SARMS) AR, NR5A1, NR5A2 MAPT 1237/4885ALOX15 3307/4885MAPK1 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.